ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
Promotion
Recombinantタンパク質s ClearClear history
Recombinantタンパク質s CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Integrin alpha 4 beta 1

Integrin alpha 4 beta 1

概要

Name:Integrin alpha-4/beta-1
Target Synonym:Integrin alpha4beta1
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品> フィルター結果
製品仕様別：
製品カテゴリー別：
種類別：
タグ別：
コンジュゲート：
製造番号 種類 製品説明 構造 純度 特徴
IT1-H82W1 Human Biotinylated Human Integrin alpha 4 beta 1 (ITGA4&ITGB1) Heterodimer Protein, His,Avitag™&Tag Free
IT1-H82W1-structure
IT1-H82W1-sds
IT1-H52W1 Human Human Integrin alpha 4 beta 1 (ITGA4&ITGB1) Heterodimer Protein, His Tag&Tag Free
IT1-H52W1-structure
IT1-H52W1-sds
ACRO Quality

生物活性データの一部

IT1-H52W1-ELISA
Integrin alpha 4 beta 1 ELISA

Immobilized Natalizumab at 1 μg/mL (100 μL/well) can bind Human ITGA4&ITGB1 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT1-H52W1) with a linear range of 1-16 ng/mL (QC tested).

Protocol
IT1-H82W1-ELISA
Integrin alpha 4 beta 1 ELISA

Immobilized Natalizumab at 1 μg/mL (100 μL/well) can bind Biotinylated Human ITGA4&ITGB1 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT1-H82W1) with a linear range of 2-31 ng/mL (QC tested).

Protocol

Synonym Name

Integrin alpha 4 beta 1,ITGA4&ITGB1,ITGA4&B1

Background

Integrins are transmembrane proteins that mediate interactions between adhesion molecules on adjacent cells and/or the extracellular matrix (ECM). Integrins have diverse roles in several biological processes including cell migration during development and wound healing, cell differentiation, and apoptosis. Their activities can also regulate the metastatic and invasive potential of tumor cells. Integrin alpha 4 beta 1(Alpha-4/beta-1) is receptors for fibronectin. Integrin alpha-4/beta-1 is a receptor for VCAM1 and recognizes the sequence Q-I-D-S in VCAM1.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Carotegrast methyl AJM-300 Approved Ea Pharma, Eisai Co Ltd Carogra Japan Colitis, Ulcerative Ea Pharma Co Ltd 2022-03-28 Colitis, Ulcerative Details
Natalizumab biosimilar(Polpharma Biologics) PB-006; DST-356A1 Approved Polpharma Biologics Sa Tyruko United States Crohn Disease; Multiple Sclerosis Sandoz Inc 2023-08-24 Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Crohn Disease Details
Natalizumab BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E Approved Biogen Inc, Perrigo Llc Tysabri, Antegran, Antegren United States Multiple Sclerosis; Crohn Disease Biogen Idec 2004-11-23 Multiple Sclerosis, Relapsing-Remitting; Epilepsies, Partial; Arthritis, Rheumatoid; Graft vs Host Disease; Stroke; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Multiple Myeloma; Demyelinating Diseases; Myositis, Inclusion Body; Crohn Disease Details
Carotegrast methyl AJM-300 Approved Ea Pharma, Eisai Co Ltd Carogra Japan Colitis, Ulcerative Ea Pharma Co Ltd 2022-03-28 Colitis, Ulcerative Details
Natalizumab biosimilar(Polpharma Biologics) PB-006; DST-356A1 Approved Polpharma Biologics Sa Tyruko United States Crohn Disease; Multiple Sclerosis Sandoz Inc 2023-08-24 Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Crohn Disease Details
Natalizumab BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E Approved Biogen Inc, Perrigo Llc Tysabri, Antegran, Antegren United States Multiple Sclerosis; Crohn Disease Biogen Idec 2004-11-23 Multiple Sclerosis, Relapsing-Remitting; Epilepsies, Partial; Arthritis, Rheumatoid; Graft vs Host Disease; Stroke; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Multiple Myeloma; Demyelinating Diseases; Myositis, Inclusion Body; Crohn Disease Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
AS-101 PRX-0001/AS101; WAX-120337; IVAX-Q-101; IVX-Q-101; CB-06-02; AS-101; PRX-001; PRX-0002/AS101 Phase 2 Clinical Biomas Ltd Alopecia; HIV Infections; Warts; Myelodysplastic Syndromes; Psoriasis; Leukemia, Myeloid, Acute; Thrombocytopenia; Macular Degeneration; Dermatitis, Atopic; Condylomata Acuminata Details
ATL-1102 ATL-1102; ATL/TV-1102; ISIS-107248; TV-1102 Phase 2 Clinical Ionis Pharmaceuticals Inc Multiple Sclerosis; Muscular Dystrophy, Duchenne Details
Alintegimod 7HP349; 7-HP-349; 7HP-349 Phase 2 Clinical 7 Hills Pharma LLC Kidney Neoplasms; Liver Neoplasms; Solid tumours; Mismatch Repair Deficient Cancer; Carcinoma, Renal Cell; Neoplasms; Skin Neoplasms; Mesothelioma; Colorectal Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
LLP2A alendronate Phase 1 Clinical University Of California Osteonecrosis; Osteoporosis; Bone Diseases, Metabolic; Bone Diseases Details
RBx-7796 RBx-7796 Clinical Sun Pharmaceutical Industries Ltd Rhinitis, Allergic; Asthma Details
AS-101 PRX-0001/AS101; WAX-120337; IVAX-Q-101; IVX-Q-101; CB-06-02; AS-101; PRX-001; PRX-0002/AS101 Phase 2 Clinical Biomas Ltd Alopecia; HIV Infections; Warts; Myelodysplastic Syndromes; Psoriasis; Leukemia, Myeloid, Acute; Thrombocytopenia; Macular Degeneration; Dermatitis, Atopic; Condylomata Acuminata Details
ATL-1102 ATL-1102; ATL/TV-1102; ISIS-107248; TV-1102 Phase 2 Clinical Ionis Pharmaceuticals Inc Multiple Sclerosis; Muscular Dystrophy, Duchenne Details
Alintegimod 7HP349; 7-HP-349; 7HP-349 Phase 2 Clinical 7 Hills Pharma LLC Kidney Neoplasms; Liver Neoplasms; Solid tumours; Mismatch Repair Deficient Cancer; Carcinoma, Renal Cell; Neoplasms; Skin Neoplasms; Mesothelioma; Colorectal Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
LLP2A alendronate Phase 1 Clinical University Of California Osteonecrosis; Osteoporosis; Bone Diseases, Metabolic; Bone Diseases Details
RBx-7796 RBx-7796 Clinical Sun Pharmaceutical Industries Ltd Rhinitis, Allergic; Asthma Details

This web search service is supported by Google Inc.

totopphone
Call us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
日本：+(0)81-50-547-99099
Email
メールアドレス
order.jp@acrobiosystems.com
Fax
ファックス
+1 888-377-6111
Address
株式会社アクロバイオシステムズ
〒157-0066
東京都世田谷区成城1丁目26番9-101号

アクロバイオシステムズの公式アカウント

linkedin twitter facebook youtube

お問い合わせ（半角英文字で入力してください）

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap